Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

Stemline Therapeutics, Inc. today announced that SL-401, the Company's lead compound, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).

10 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Sanfilippo syndrome compromises blood-brain barrier, leads to brain damage

A study into the effects of Sanfilippo Syndrome type B (MPS III B) has found that the barrier responsible for protecting the brain from the entry of harmful blood-borne substances is structurally and functionally damaged by the devastating disease. University of South Florida researchers identified damage in specific brain structures involved in the pathology of MPS III B, one of four Sanfilippo syndromes, all of which are inherited diseases of metabolism.

9 Mar 2011

New clinical trial to prevent aggressive type of breast cancer

In a first-of-its-kind clinical trial, physician-scientists at University Hospitals Case Medical Center are exploring a new method to potentially prevent recurrence of an early stage, aggressive type of breast cancer.

9 Mar 2011

Researchers use qMRI to confirm effect of CS treatment in patients with OA

A group of Canadian researchers led by Prof. Jean-Pierre Pelletier, Head of the Osteoarthritis Research Unit at the University of Montreal Hospital Research Centre, published a clinical trial in which they confirm, for the first time using quantitative Magnetic Resonance Imaging, the disease modifying effects of chondroitin sulphate, a symptomatic slow acting drug for osteoarthritis.

5 Mar 2011

ThermoGenesis prices offering of 2,250,000 shares of common stock

ThermoGenesis Corp., a leading supplier of innovative products and services that process and store adult stem cells, said today that it has determined the pricing for an offering of shares and warrants.

4 Mar 2011

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Sangamo BioSciences, Inc. announced that data from its programs to develop ZFN-based therapeutic approaches for the treatment of HIV/AIDS were discussed in four oral presentations at the 18th Conference on Retroviruses and Opportunistic Infections, held in Boston from February 27 to March 2, 2011.

4 Mar 2011

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).

4 Mar 2011

Rockwell Medical fourth quarter net loss increases to $1.7 million

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported today fourth quarter and full-year 2010 results.

3 Mar 2011

International consortium of researchers genetically characterise Spanish Fanconi anaemia patients

A consortium of thirty-two researchers worldwide, led by Dr Jordi Surrallés, professor of the Department of Genetics and Microbiology at Universitat Autònoma de Barcelona (UAB) and member of the Centre for Biomedical Network Research on Rare Diseases (CIBERER), genetically and clinically characterised almost all Spanish patients suffering from Franconi anaemia, a rare disease affecting one in every 500,000 persons and which is characterised by severe anaemia in children, congenital malformations and a high predisposition to cancer.

3 Mar 2011

Mathematical model predicts lifespan of stem cells

When patients receive a bone marrow transplant, they are getting a new population of hematopoietic stem cells. Fresh stem cells are needed when a patient is low on red blood cells, as in anemia, or white blood cells, which can be caused by cancer or even cancer treatments such as irradiation or chemotherapy. The problem is that a bone marrow transplant might not succeed because the transplanted stem cells don't live long enough or because they proliferate too well, leading to leukemia.

2 Mar 2011

Bone marrow stem cell transplantation feasible, safe treatment for children with severe traumatic brain injury

For children with severe traumatic brain injury (TBI), transplantation of stem cells derived from the patients' own bone marrow is a "logistically feasible and safe" treatment procedure, reports the March issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

2 Mar 2011

Viewpoints: GOP Govs. on Medicaid 'flexibility'; 'attack' on planned parenthood; following doctors' orders not so easy

Medicaid is bureaucratic and costly, and the stimulus and new federal health care law have made a bad problem even worse, shackling states with unrealistic mandates.

2 Mar 2011

U-M's SIVQ software-tool can pinpoint cell and tissue samples more accurately

Ulysses Balis, M.D., clicks a mouse to identify a helicopter in a satellite photo of Baghdad, Iraq. With another click, an algorithm that he and his team designed picks out three more choppers without highlighting any of the buildings, streets, trees or cars.

1 Mar 2011

PAH closely related to bone marrow abnormalities

Results from a study published in Blood, the Journal of the American Society of Hematology reveal a close relationship between pulmonary arterial hypertension (PAH)-exceedingly high blood pressure in the arteries carrying blood from the heart to the lungs-and abnormalities of the blood-forming cells in the bone marrow (known as myeloid abnormalities).

1 Mar 2011

Omni Bio to expand Type 1 diabetes Phase I/II trial from 15 to 50 patients

Omni Bio Pharmaceutical, Inc., an emerging biopharmaceutical company formed to acquire, license, and develop existing therapies for indications with substantial commercialization potential, has committed to expand its Phase I/II human clinical trial in recently diagnosed Type 1 diabetes patients from 15 patients to 50.

28 Feb 2011

BrainStorm raises $3.6 million through private placement financing

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into securities purchase agreements with certain institutional and other investors in connection with a private placement financing in reliance upon Regulation S. BrainStorm received gross proceeds of approximately $3.6 million resulting from the sale of shares at a purchase price of $0.28 per share at the closing of the transaction.

28 Feb 2011

FDA approves GSK's PROMACTA to treat rare blood disorder

GlaxoSmithKline today announced that the United States Food and Drug Administration granted full approval for PROMACTA, an oral tablet that can raise platelet counts in patients with the rare blood disorder chronic immune thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

27 Feb 2011

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that encouraging preliminary results of a Phase 2 trial of ganetespib as a single agent in non-small cell lung cancer were presented at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

27 Feb 2011

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of the first reported case in which adenovirus infection was successfully eradicated following treatment with its broad-spectrum antiviral drug, CMX001.

25 Feb 2011

Bone Marrow News and Research

Further Reading

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Sanfilippo syndrome compromises blood-brain barrier, leads to brain damage

New clinical trial to prevent aggressive type of breast cancer

Researchers use qMRI to confirm effect of CS treatment in patients with OA

ThermoGenesis prices offering of 2,250,000 shares of common stock

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Rockwell Medical fourth quarter net loss increases to $1.7 million

International consortium of researchers genetically characterise Spanish Fanconi anaemia patients

Mathematical model predicts lifespan of stem cells

Bone marrow stem cell transplantation feasible, safe treatment for children with severe traumatic brain injury

Viewpoints: GOP Govs. on Medicaid 'flexibility'; 'attack' on planned parenthood; following doctors' orders not so easy

U-M's SIVQ software-tool can pinpoint cell and tissue samples more accurately

PAH closely related to bone marrow abnormalities

Omni Bio to expand Type 1 diabetes Phase I/II trial from 15 to 50 patients

BrainStorm raises $3.6 million through private placement financing

FDA approves GSK's PROMACTA to treat rare blood disorder

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News